Skip to Content

Olaparib

In the US, Olaparib (olaparib systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Ovarian Cancer.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XX46

CAS registry number (Chemical Abstracts Service)

0763113-22-0

Chemical Formula

C24-H23-F-N4-O3

Molecular Weight

434

Therapeutic Category

Antineoplastic agent: PARP inhibitor

Chemical Name

4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one

Foreign Names

  • Olaparibum (Latin)
  • Olaparib (German)
  • Olaparib (French)
  • Olaparib (Spanish)

Generic Names

  • Olaparib (OS: USAN)
  • Olaparib (OS: JAN)
  • UNII-WOH1JD9AR8 (IS)

Brand Names

  • Lynparza
    AstraZeneca, Switzerland; AstraZeneca, Germany; AstraZeneca, France; AstraZeneca, Croatia (Hrvatska); AstraZeneca, Poland; AstraZeneca, United States; AstraZeneca UK, United Kingdom

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide